<DOC>
	<DOC>NCT01940133</DOC>
	<brief_summary>This study is a Phase I, open label study to determine the Maximum Tolerated Dose(MTD) and the Recommended Phase II Dose (RP2D) in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309</brief_title>
	<detailed_description />
	<criteria>Histologically or cytologically confirmed diagnosis of advanced solid tumor for which no therapy of proven efficacy is available. Age â‰¥ 18 Evidence of tumor progression with measurable or evaluable disease. Use of adequate contraceptive measures for male patients. Eastern Cooperative Oncology Group (ECOG) Performance Score of 01. Signed informed consent. Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifier, signal transduction inhibitors) Patients with a history of myocardial infarction or coronary artery bypass within the last 3 years. Patients with severe/unstable angina, coronary/peripheral arterial bypass, symptomatic congestive heart failure NYHA Class 3 or 4, hypertension BP&gt;150/100mmHg. Prediagnosed diabetes mellitus. Fasting glucose &gt; 7.0 mmol/L or HbA1c &gt; 6%.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>